Journal of Infection
Volume 64, Issue 4 , Pages 399-408, April 2012

Predictors of travel-related hepatitis A and B among native adult Danes: A nationwide case-control study

  • Ulla Schierup Nielsen

      Affiliations

    • Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus N, Denmark
    • Corresponding Author InformationCorresponding author. Tel.: +45 30289283; fax: +45 89498360.
  • ,
  • Reimar Wernich Thomsen

      Affiliations

    • Department of Clinical Epidemiology, Aarhus University Hospital, 8200 Aarhus N, Denmark
  • ,
  • Susan Cowan

      Affiliations

    • Department of Epidemiology, Statens Serum Institut, 2300 Copenhagen S, Denmark
  • ,
  • Carsten Schade Larsen

      Affiliations

    • Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus N, Denmark
  • ,
  • Eskild Petersen

      Affiliations

    • Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus N, Denmark

Accepted 20 December 2011. published online 26 December 2011.

Summary 

Objectives

To assess journey length and other predictors of travel-related acute hepatitis A (HAV) and B (HBV) virus infection among native Danes and determine the sensitivity and specificity of current pre-travel vaccination guidelines.

Methods

A nationwide case-control study was perfomed involving 60 Danes with HAV and 14 with HBV who acquired hepatitis in non-western countries from 2000 to 2010. Non-immune travellers from a nationwide survey (1188 HAV and 1709 HBV) served as controls.

Results

The odds ratios (ORs) for HAV and HBV increased with increasing journey length (p<0.0001). However, 90% of HAV and 62% of HBV cases travelled for less than 4 weeks, and the daily infection rate did not increase with journey length; rather, for HAV it decreased. Increasing age (p<0.0001) and journeys to Africa (OR 6.1 (3.2–11)) raised the risk of acute HAV. Travelling alone or with friends as compared to travelling with a partner/family (OR: 15 (3.2–134)) strongly predicted HBV risk. Danish vaccination guidelines had HAV/HBV sensitivities of 86%/31%, and specificities of 27%/95%, respectively. Incidence rates were 12.8 (HAV) and 10.2 (HBV) per 100,000 non-immune travel months, and acute disease severity affected HAV and HBV cases equally.

Conclusions

These results may support revision of current pre-travel vaccination guidelines.

Keywords: Hepatitis, Immunization, Travel, Travel medicine, Practice guidelines, Epidemiology, Case-control studies, Risk factors

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0163-4453(11)00605-0

doi:10.1016/j.jinf.2011.12.013

Journal of Infection
Volume 64, Issue 4 , Pages 399-408, April 2012